Priovant enrolls first patients in Phase 3 brepocitinib CS trial
Priovant Therapeutics has dosed the first patients in BEACON+, its Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), a chronic inflammatory skin condition that affects an estimated 40,000 adults in the United States and for which no FDA-approved therapy currently exists.
The trial will enrol approximately 140 patients across roughly 70 sites worldwide, randomising participants 3:2 between brepocitinib 45 mg once daily and placebo. The primary endpoint is the proportion of patients achieving at least a 50% reduction in the Cutaneous Sarcoidosis Activity and Morphology Instrument Activity Score (CSAMI-A) at Week 16. Priovant expects to report topline data in calendar year 2028.
Phase 2 foundation and FDA designation
BEACON+ is structured as a Part B continuation of the Phase 2 BEACON study, which Priovant describes as the first positive placebo-controlled trial ever conducted in CS. In that earlier study, 77% of patients on the 45 mg dose met the same CSAMI-A endpoint, compared with 0% on placebo, a result that secured brepocitinib FDA Breakthrough Therapy Designation for the indication.
Brepocitinib is a dual inhibitor of TYK2 and JAK1. Through that mechanism it suppresses a cluster of cytokines implicated in autoimmune inflammation, including type I and type II interferons, IL-6, IL-12 and IL-23, via a single once-daily oral tablet. Priovant positions this cytokine profile as well matched to granulomatous and autoimmune skin diseases, though formal comparative evidence against other JAK or TYK2 inhibitors in CS has not yet been published.
Beyond CS, Priovant is pursuing brepocitinib across three additional rare indications. A New Drug Application in dermatomyositis (DM) is under Priority Review at the FDA, with a PDUFA action date expected before the end of September 2026. The Phase 3 CLARITY trial in non-infectious uveitis is anticipated to read out later in 2026. A Phase 2b/3 study in lichen planopilaris is also actively enrolling.
Market context and competitive landscape
Cutaneous sarcoidosis sits within a broader rare autoimmune dermatology space that has attracted increasing drug-development attention over the past several years, driven partly by the commercial success of JAK inhibitors in atopic dermatitis and alopecia areata. Selective TYK2 inhibition has gained particular momentum since Bristol Myers Squibb's deucravacitinib received FDA approval in plaque psoriasis in 2022, validating the target class. Priovant is one of the few companies to have advanced a TYK2/JAK1 programme explicitly into rare inflammatory skin diseases beyond psoriasis.
The CS patient population is relatively small and disproportionately affects Black Americans, a demographic historically under-represented in clinical research, which adds both an ethical dimension to trial design and a commercial consideration around addressable market size. Priovant has not disclosed peak sales projections for the programme.
Chief executive Ben Zimmer said the CS Phase 3 initiation reflects the company's aim to establish brepocitinib "as a leading treatment option across multiple rare diseases with high patient burden and few or no alternative therapies." With a potential DM approval approaching and three additional Phase 3 programmes active or enrolling, the coming twelve months represent a period of unusually concentrated clinical and regulatory activity for a company of Priovant's scale. Investors in parent company Roivant Sciences will be watching the DM PDUFA outcome as the most immediate readout of brepocitinib's commercial potential.